Clinical trials: Idiopathic Multicentric Castleman's Disease
Idiopathic Multicentric Castleman's Disease
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
- Trial name
- SISREMCAD (NCT04838860)
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RECORDATI GROUP
Castleman Disease, Angiofollicular Lymphoid Hyperplasia
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction.
- Conditions
- Castleman Disease, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia
- Trial name
- NCT02853968
- Testing
- Blood draw/buccal swab
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Castleman Disease, Castleman's Disease, Multicentric
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
- Trial name
- NCT03933904
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania